Value-based cancer care and the excessive cost of drugs
Menée aux Etats-Unis, cette étude analyse le rapport coût-efficacité de l'ajout du necitumumab à une chimiothérapie standard de première ligne pour traiter les patients atteints d'un cancer métastatique du poumon à cellules squameuses
On March 19, 2015, the US Congress repealed the Sustainable Growth Rate Formula as the mechanism to control Medicare spending on physician services and introduced a new merit-based payment system aiming to link financing of health care with performance and “value.” Although the law focuses on the value-based purchasing of existing health services, it inevitably raises the issue of what is the acceptable value as a basis for allowing health services to be introduced in practice. (Regulatory agencies such as the US Food and Drug Administration [FDA] have typically not been concerned about value.)
JAMA Oncology , commentaire, 2014